Pulmonary nocardiosis in patients with underlying pulmonary alveolar proteinosis: a case series and review of the literature Authors: Qi Chen, Ruxuan Chen, Zhiyi Li, Yujie Shi, Kai Xu, Chi Shao, Hui Huang Published: 2026 ABSTRACT ObjectivesPulmonary alveolar proteinosis (PAP) and pulmonary nocardiosis are relatively rare, their co-occurrence constitutes a clinically important comorbidity. Nocardia infection exhibits variable clinical manifestations, and carries a substantial risk of mortality in the absence of timely, pathogen-directed antimicrobial therapy. This study aims to summarize the clinical features of Nocardia infection in PAP patients.Case presentationWe present four confirmed cases of PAP complicated by Nocardia infection. These cases illustrate the distinct microbial species, disease courses and clinical outcomes. The duration of Nocardia infection among the four patients ranged from 3 months to over 2 years. All patients received anti-infection treatment guided by antimicrobial susceptibility testing (AST) results. Clinical outcomes included microbiological cure of infection, sustained clinical stability without progression, and all-cause mortality.ConclusionsIn patients with PAP, the emergence of fever and new pulmonary opacities warrants strong clinical suspicion for Nocardia infection. Early initiation of pathogen-directed antimicrobial therapy is critical for infection control and enables subsequent PAP stabilization, clinical recovery, and the safe performance of whole-lung lavage.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12890-026-04527-1. Background Pulmonary alveolar proteinosis (PAP) is an uncommon interstitial lung disease marked by the abnormal deposition of pulmonary surfactant within the alveolar lumen and resident macrophages. The pathogenesis primarily involves alveolar macrophage dysfunction in pulmonary surfactant clearance or dysregulation of pulmonary surfactant production [1]. According to current consensus classifications, PAP comprises five etiologic subtypes: autoimmune, secondary, hereditary, congenital, and unclassified [1, 2]. Autoimmune PAP (aPAP), defined by the presence of neutralizing autoantibodies targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), represents the predominant form of PAP in adults, comprising roughly 90% of cases. Secondary PAP, which is associated with underlying conditions such as hematologic malignancies, immunosuppression, chronic inflammatory disorders, occupational dust exposure, and opportunistic infections, represents 5–10% of cases [3]. Patients with PAP exhibit profound dysfunction of alveolar macrophages and neutrophils, resulting in increased susceptibility to infectious complications, especially lower respiratory tract infections [4]. Concurrent infectious complications occur in 5–13% of PAP patients and constitute a major determinant of clinical outcomes. Infection-attributable mortality accounts for 18–20% of all-cause deaths in contemporary PAP cohort studies [4–7]. In patients with PAP complicated by infectious diseases, the common etiologic agents include opportunistic pathogens such as Nocardia spp., mycobacteria, and fungi, among which Nocardia spp. are the most frequently identified [4]. Nocardia infection contributes to approximately 4.8% of all-cause mortality in PAP patients [7]. Nocardia is a Gram-positive, aerobic, facultatively intracellular, filamentous bacillus widely distributed in soil, water, and organic-rich environments, and is an established cause of severe opportunistic infection [8]. Nocardiosis predominantly affects immunocompromised hosts as well as individuals with chronic structural lung disease. Inhalation via the respiratory tract is the predominant route of infection, with the lungs serving as the most frequently involved site [9, 10]. In a prior institutional cohort study (1990–2010), we identified PAP as a significant susceptibility factor for pulmonary nocardiosis among immunocompetent individuals [11]. Co-infection with Nocardia in patients with PAP not only exacerbates clinical symptom but also contraindicates whole-lung lavage (WLL), thereby significantly impairing prognosis. Although both PAP and pulmonary nocardiosis are relatively rare, their co-occurrence constitutes a clinically important comorbidity: pulmonary nocardiosis is the most frequently reported infectious complication in PAP cohorts. To address this underrecognized clinical challenge, we report the clinical, microbiological, and radiological features of 4 patients with PAP complicated by Nocardia infection. These patients exhibited distinct disease courses and outcomes, providing valuable insights into the diagnosis and management of such conditions. Case presentations Case 1 A 42-year-old male presented with a one-month history of fever, cough, and productive sputum. He had a 40-pack-year smoking history. Seven years earlier, he was diagnosed with PAP and emphysema following lung biopsy performed for chronic cough and exertional dyspnea. Given sustained clinical and radiographic stability of PAP, no disease-modifying interventions, such as whole-lung lavage, were performed. On admission, sputum culture confirmed Nocardia farcinica infection (clinical, laboratory, and imaging features of the four patients are summarized in Table 1). Chest CT demonstrated a solitary pulmonary nodule and emphysematous changes. Laboratory evaluation revealed systemic inflammation and mild hypoxemia: CRP 25.9 mg/L (ref: 0–3 mg/L), ESR 62 mm/h (ref: 0–20 mm/h), white blood cell (WBC) count 12.71 × 10⁹/L (ref: 3.5–9.5 × 10⁹/L), neutrophil (‌NEUT‌) count 9.87 × 10⁹/L (ref: 2–7.5 × 10⁹/L), and PaO₂ 8.246 kPa (ref: 10.64–13.3 kPa). Based on antimicrobial susceptibility testing (AST), he received combination therapy with ceftazidime and moxifloxacin. After one month of treatment, the patient exhibited an improvement in clinical symptoms. A follow-up chest CT at a local facility confirmed complete radiological resolution of the nodule and no progression of PAP-associated radiological findings was observed. However, the patient discontinued antimicrobial therapy prematurely without medical guidance. At two-year follow-up, he remained asymptomatic with stable chest imaging. Table 1Clinical, laboratory and imaging characteristics of Patients with Pulmonary Alveolar Proteinosis Complicated by Nocardia InfectionCharacteristicsCase1Case2Case3Case4Age at Nocardia Infection (years)42516157GenderMMFMPast Medical HistoryEmphysemaDiabetes, bronchiectasis-DiabetesSmoking HistoryYYNYInterval a (months)88360231PAP Diagnostic ApproachPercutaneous pulmonary tissue biopsyBALF pathology and anti-GM-CSF antibodyBALF pathologyTBLB biopsyInfection SymptomsFever, cough, expectorationFever, cough, dyspneaFever, cough, expectoration, dyspneaFever, expectoration, exacerbated dyspneaImaging manifestations of infectionSolitary pulmonary nodulePulmonary mass with cavity, bronchiectasisPulmonary mass with cavityNew patchy opacities, hydropneumothoraxSite of InfectionLungLungLungLung, thoracic cavityNocardia Species Nocardia farcinica Nocardia cyriacigeorgica Nocardia asteroides Unidentified Nocardia speciesCulture-Positive SpecimenSputumBALFBALFPleural fluidCo-infection-Pulmonary NTMb infectionCMV viremia, Oral candidiasis, Urinary tract infectionTinea unguiumTreatment for PAPConservative treatmentGM-CSF nebulization, Whole-lung lavageConservative treatmentWhole-lung lavageTreatment for Nocardia infectionCefotaxime, moxifloxacinSMZ-TMP, moxifloxacin, carbapenem, minocyclineSMZ-TMP, moxifloxacin, cefotaxime, cefoperazone sulbactamceftriaxone, amikacin, minocyclineInfection OutcomeClinical cure of infectionClinical improvementDeathcClinical improvementFollow-up Duration (Months)285514BALF Bronchoalveolar lavage fluid, CMV Cytomegalovirus, GM-CSF Granulocyte-macrophage colony-stimulating factor, NTM Nontuberculous mycobacteria, PAP Pulmonary alveolar proteinosis, TBLB Transbronchial lung biopsy, SMZ-TMP Sulfamethoxazole-trimethoprima Interval from the onset of PAP to the development of Nocardia infectionb Mycobacterium avium-intracellulare complexc Cause of death: septic shock Table 1Clinical, laboratory and imaging characteristics of Patients with Pulmonary Alveolar Proteinosis Complicated by Nocardia InfectionCharacteristicsCase1Case2Case3Case4Age at Nocardia Infection (years)42516157GenderMMFMPast Medical HistoryEmphysemaDiabetes, bronchiectasis-DiabetesSmoking HistoryYYNYInterval a (months)88360231PAP Diagnostic ApproachPercutaneous pulmonary tissue biopsyBALF pathology and anti-GM-CSF antibodyBALF pathologyTBLB biopsyInfection SymptomsFever, cough, expectorationFever, cough, dyspneaFever, cough, expectoration, dyspneaFever, expectoration, exacerbated dyspneaImaging manifestations of infectionSolitary pulmonary nodulePulmonary mass with cavity, bronchiectasisPulmonary mass with cavityNew patchy opacities, hydropneumothoraxSite of InfectionLungLungLungLung, thoracic cavityNocardia Species Nocardia farcinica Nocardia cyriacigeorgica Nocardia asteroides Unidentified Nocardia speciesCulture-Positive SpecimenSputumBALFBALFPleural fluidCo-infection-Pulmonary NTMb infectionCMV viremia, Oral candidiasis, Urinary tract infectionTinea unguiumTreatment for PAPConservative treatmentGM-CSF nebulization, Whole-lung lavageConservative treatmentWhole-lung lavageTreatment for Nocardia infectionCefotaxime, moxifloxacinSMZ-TMP, moxifloxacin, carbapenem, minocyclineSMZ-TMP, moxifloxacin, cefotaxime, cefoperazone sulbactamceftriaxone, amikacin, minocyclineInfection OutcomeClinical cure of infectionClinical improvementDeathcClinical improvementFollow-up Duration (Months)285514BALF Bronchoalveolar lavage fluid, CMV Cytomegalovirus, GM-CSF Granulocyte-macrophage colony-stimulating factor, NTM Nontuberculous mycobacteria, PAP Pulmonary alveolar proteinosis, TBLB Transbronchial lung biopsy, SMZ-TMP Sulfamethoxazole-trimethoprima Interval from the onset of PAP to the development of Nocardia infectionb Mycobacterium avium-intracellulare complexc Cause of death: septic shock Clinical, laboratory and imaging characteristics of Patients with Pulmonary Alveolar Proteinosis Complicated by Nocardia Infection BALF Bronchoalveolar lavage fluid, CMV Cytomegalovirus, GM-CSF Granulocyte-macrophage colony-stimulating factor, NTM Nontuberculous mycobacteria, PAP Pulmonary alveolar proteinosis, TBLB Transbronchial lung biopsy, SMZ-TMP Sulfamethoxazole-trimethoprim a Interval from the onset of PAP to the development of Nocardia infection b Mycobacterium avium-intracellulare complex c Cause of death: septic shock Case 2 A 51-year-old male presented with progressive cough and exertional dyspnea of 3 months’ duration, accompanied by 5 days of fever. His medical history included type 2 diabetes mellitus, bronchiectasis, and a 60-pack-year smoking history. Thirty years earlier, he developed chronic cough and exertional dyspnea but remained undiagnosed and untreated. Three months prior to admission, symptom progression prompted evaluation at an outside hospital, where chest CT revealed diffuse bilateral pulmonary opacities, leading to an initial diagnosis of interstitial pneumonia and empirical glucocorticoid therapy (methylprednisolone 8 mg twice daily for 3 months). After admission, the glucocorticoid was gradually reduced and discontinued. HRCT demonstrated bilateral, multi-lobar ground-glass opacities (GGOs), fine reticular opacities, focal cavitation, and characteristic ‘paving stone sign’ and ‘map-like sign’ (Fig. 1a-c). Definitive diagnosis of autoimmune PAP (aPAP) was established via BALF cytology showing PAS-positive lipoproteinaceous material and positive serum anti-GM-CSF autoantibodies. Laboratory evaluation revealed mild systemic inflammation: CRP 12.68 mg/L (ref: 0–3 mg/L), ESR 18 mm/h (ref: 0–20 mm/h), WBC 10.9 × 10⁹/L (ref: 3.5–9.5 × 10⁹/L), and ‌NEUT‌ 8.09 × 10⁹/L (ref: 2–7.5 × 10⁹/L). At the time of aPAP diagnosis, BALF culture isolated Nocardia cyriacigeorgica and Mycobacterium avium-intracellulare complex (MAC). Antimicrobial therapy was individualized based on AST results: sulfamethoxazole-trimethoprim (SMZ-TMP), moxifloxacin, meropenem and minocycline for nocardiosis; and rifampin, ethambutol, and clarithromycin for MAC infection. Concurrently, nebulized GM-CSF was initiated to address underlying aPAP. After 3 months of combined treatment, clinical improvement was evident. Follow-up chest CT confirmed radiological resolution of infectious lesions (Fig. 1d-f); repeat BALF culture was sterile. Subsequently, the patient underwent therapeutic whole-lung lavage (WLL) for aPAP, followed by maintenance nebulized GM-CSF. At long-term follow-up, he remained asymptomatic with sustained radiological improvement (Fig. 1g-i). Fig. 1Chest high-resolution computed tomography (HRCT) findings of Case 2. a-c (October 2021, pretreatment): Bilateral multifocal ground-glass opacities (GGOs) and fine reticular opacities, consistent with the classic ‘paving stone sign’. A cavitary mass was identified in the left upper lobe, associated with localized bronchiectasis. d-f (January 2022, post-treatment): Following 3 months of combination anti-infective therapy and inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), and 2 days after whole-lung lavage: Persistent bilateral GGOs and fine reticular opacities were observed, with partial progression and partial resolution compared to baseline. The cavitary lesion in the left upper lobe showed radiographic absorption, leaving residual linear opacities and persistent localized bronchiectasis. g-i (May 2025, long-term follow-up): After > 3 years of continuous inhaled GM-CSF therapy, the reduction in bilateral GGOs and fine reticular opacities was evident and no progression of the left upper lobe abnormality was observed Chest high-resolution computed tomography (HRCT) findings of Case 2. a-c (October 2021, pretreatment): Bilateral multifocal ground-glass opacities (GGOs) and fine reticular opacities, consistent with the classic ‘paving stone sign’. A cavitary mass was identified in the left upper lobe, associated with localized bronchiectasis. d-f (January 2022, post-treatment): Following 3 months of combination anti-infective therapy and inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), and 2 days after whole-lung lavage: Persistent bilateral GGOs and fine reticular opacities were observed, with partial progression and partial resolution compared to baseline. The cavitary lesion in the left upper lobe showed radiographic absorption, leaving residual linear opacities and persistent localized bronchiectasis. g-i (May 2025, long-term follow-up): After > 3 years of continuous inhaled GM-CSF therapy, the reduction in bilateral GGOs and fine reticular opacities was evident and no progression of the left upper lobe abnormality was observed Case 3 A 61-year-old woman presented with progressive exertional dyspnea and nonproductive cough of 2-month duration, followed by fever, cough, and expectoration for 1 week. She had a documented occupational history of asbestos exposure spanning over three decades. Two months prior to admission, she underwent evaluation at an external institution for presumed community-acquired pneumonia and received empiric antibiotic therapy with a third-generation cephalosporin and a fluoroquinolone. However, no clinical improvement was observed. Subsequent chest CT revealed bilateral, symmetric, diffuse GGOs with interlobular septal thickening, prompting consideration of interstitial lung disease. She was subsequently treated with oral prednisone (25 mg daily) for approximately 4 weeks, but discontinued therapy due to lack of symptomatic or radiographic response. On admission, laboratory evaluation demonstrated marked systemic inflammation: ESR 53 mm/h (ref: 0–20 mm/h), WBC count 15.79 × 10⁹/L (ref: 3.5–9.5 × 10⁹/L), NEUT count 13.09 × 10⁹/L (ref: 2–7.5 × 10⁹/L). HRCT confirmed extensive crazy-paving opacities, patchy consolidation, areas of ground-glass attenuation, and newly developed cavitary lesions in the right upper lobe. BALF was turbid and milky in appearance. BALF culture yielded Nocardia asteroides. Based on AST results, combination therapy with ceftazidime, moxifloxacin, and SMZ-TMP was initiated, leading to transient stabilization of respiratory status and reduction in supplemental oxygen requirements. However, on the 8th hospital day, the patient experienced clinical deterioration, with fever (39–42 °C) and progressive worsening of oxygenation. Serial sputum cultures grew Candida albicans, urine culture isolated Enterococcus faecium, and blood cytomegalovirus (CMV)-DNA was positive. Cefoperazone-sulbactam and ganciclovir were added per susceptibility results, but no significant improvement was observed in symptoms, oxygenation index, or inflammatory markers. On the 18th hospital day, she developed septic shock, and she died on hospital day 22. For the diagnosis of PAP, due to the patient’s critical condition and rapid disease progression, only BALF pathological examination was performed. The diagnosis was confirmed by the combination of typical chest imaging findings and the presence of homogeneous eosinophilic fine granular deposits positive for D-PAS staining in BALF. No specific treatment for PAP was administered due to her critical status. Case 4 A 57-year-old male presented with progressive dyspnea, fever, cough, and productive sputum for 3 months. His medical history included poorly controlled type 2 diabetes mellitus, a heavy smoking history (120 pack-years), and occupational xylene exposure for 2 consecutive years. Over 2 years prior, he was diagnosed with PAP via transbronchial lung biopsy (TBLB) due to exertional dyspnea. One year before the current presentation, he underwent therapeutic whole-lung lavage with partial symptomatic relief. Three months prior, he developed left-sided pleural effusion at an external facility, where tuberculous pleurisy was suspected. He received empirical anti-tuberculosis therapy with isoniazid, rifampicin, ethambutol, and amikacin for 3 months. The regimen was discontinued due to lack of clinical or radiological improvement. Upon admission, laboratory tests revealed an ESR of 40 mm/h (ref: 0–20 mm/h), WBC count of 7.57 × 10⁹/L (ref: 3.5–9.5 × 10⁹/L), and NEUT count of 5.35 × 10⁹/L (ref: 2–7.5 × 10⁹/L). HRCT demonstrated the ‘map-like sign’, new bilateral patchy consolidations, and left-sided hydropneumothorax. Pleural fluid culture was positive for Nocardia spp. (species-level identification not achievable due to limited isolate growth). Based on AST results, combination anti-Nocardia therapy was initiated with ceftriaxone, amikacin, and minocycline. After 4 months of continuous treatment, the patient’s clinical symptoms resolved, and follow-up HRCT showed partial resolution of pulmonary opacities. Given the stable control of PAP, no PAP-specific therapy (e.g., repeat WLL, GM-CSF supplementation) was administered during this admission. The patient was lost to follow-up after discharge. Discussion and conclusions A literature review was conducted using search terms (title or abstract) combining pulmonary alveolar proteinosis AND Nocardia, limiting results to English-language publications from January 2010 through December 2025 (Table 2). Of 6 identified cases, 4 (66.7%) focused on PAP combined with Nocardia brain abscess. Only two cases described PAP complicated by Nocardia pulmonary infection. In addition, Punatar AD et al. reviewed 75 patients with PAP complicated by opportunistic infections from 1950 to 2010, of whom 32 (43%) had Nocardia infections [12]. However, no detailed case characteristics were reported. To our knowledge, this is the first case series of pulmonary nocardiosis combined with PAP. Table 2Published case reports of PAP with Nocardia infectionCharacteristicsCase1Case2Case3Case4Case5Case6Author & YearPunatar AD./2012 [12]Shirani K./2014 [13]Carrasco García de León S./2017 [14]Berthoux C./2021 [15]Wu XK./2021 [16]Ekici S./2019[17]Age/SexM/65M/42M/49M/40M/45M/62SymptomssyncopeFever, headache, vomitingmotor aphasia, central facial palsy, seizuresheadache, facial paralysis, brachial deficitrespiratory exertion, coughfever, night sweats, chest painInfection siteCNSCNSCNSCNSLungLungNocardia Species Nocardia farcinica Nocardia asteroides Unidentified Nocardia species Nocardia abscessus Unidentified Nocardia species Nocardia brasiliensis Elevated GM-CSF AutoantibodiesNot performedNot performedNot performedYesYesYesTreatmentNASMZ-TMP, meropenem, amikacine, dexamethasoneamoxicillin/clavulanic acid, minocyclineSMZ-TMP, meropenemSMZ-TMPSMZ-TMP, amikacine, moxifloxacinDuration of treatment12 months6 months12 months18 months6 months8 monthsDuration of Follow32 months6 months15 years18 months26 monthsNAOutcomeClinical cure of infectionRecurrent symptomsClinical cure of infectionClinical cure of infectionClinical improvementClinical cure of infectionPAP Pulmonary alveolar proteinosis, CNS Central nervous system, SMZ-TMP sulfamethoxazole-trimethoprim, GM-CSF Granulocyte-macrophage colony-stimulating factor, NA not available Table 2Published case reports of PAP with Nocardia infectionCharacteristicsCase1Case2Case3Case4Case5Case6Author & YearPunatar AD./2012 [12]Shirani K./2014 [13]Carrasco García de León S./2017 [14]Berthoux C./2021 [15]Wu XK./2021 [16]Ekici S./2019[17]Age/SexM/65M/42M/49M/40M/45M/62SymptomssyncopeFever, headache, vomitingmotor aphasia, central facial palsy, seizuresheadache, facial paralysis, brachial deficitrespiratory exertion, coughfever, night sweats, chest painInfection siteCNSCNSCNSCNSLungLungNocardia Species Nocardia farcinica Nocardia asteroides Unidentified Nocardia species Nocardia abscessus Unidentified Nocardia species Nocardia brasiliensis Elevated GM-CSF AutoantibodiesNot performedNot performedNot performedYesYesYesTreatmentNASMZ-TMP, meropenem, amikacine, dexamethasoneamoxicillin/clavulanic acid, minocyclineSMZ-TMP, meropenemSMZ-TMPSMZ-TMP, amikacine, moxifloxacinDuration of treatment12 months6 months12 months18 months6 months8 monthsDuration of Follow32 months6 months15 years18 months26 monthsNAOutcomeClinical cure of infectionRecurrent symptomsClinical cure of infectionClinical cure of infectionClinical improvementClinical cure of infectionPAP Pulmonary alveolar proteinosis, CNS Central nervous system, SMZ-TMP sulfamethoxazole-trimethoprim, GM-CSF Granulocyte-macrophage colony-stimulating factor, NA not available Published case reports of PAP with Nocardia infection PAP Pulmonary alveolar proteinosis, CNS Central nervous system, SMZ-TMP sulfamethoxazole-trimethoprim, GM-CSF Granulocyte-macrophage colony-stimulating factor, NA not available Nocardia species are opportunistic aerobic actinomycetes that predominantly cause infection in individuals with impaired cellular immunity, particularly those undergoing cytotoxic chemotherapy, solid-organ or hematopoietic stem cell transplantation, or prolonged glucocorticoid therapy [10]. However, approximately one-third of nocardiosis cases occur in patients without immunosuppression [10–11, 18–19]. Following respiratory inhalation, Nocardia evades innate immune clearance by resisting phagolysosomal fusion and replicating intracellularly within alveolar macrophages. This intracellular survival strategy renders individuals with intrinsic macrophage dysfunction particularly vulnerable to infection. Therefore, individuals with macrophage dysfunction represent a high-risk population for Nocardia infection, encompassing patients with chronic granulomatous disease and anti-GM-CSF autoantibody-positive cases. The majority of patients with PAP exhibit GM-CSF dysfunction, which leads to pulmonary surfactant pathological accumulation in the alveolar space [2]. As GM-CSF is essential for the functional maturation and effector activities of alveolar macrophages and neutrophils, including antigen presentation, phagocytosis, and chemotaxis [18], GM-CSF deficiency results in defective pathogen recognition, reduced microbial killing, and diminished recruitment of innate immune cells, collectively compromising host defense against respiratory pathogens. Among the four PAP patients with Nocardia infection in our study, comorbidities or immunomodulatory exposures included emphysema, uncontrolled diabetes mellitus, and prior glucocorticoid therapy, each representing an independent risk factor for opportunistic pulmonary infection. PAP markedly increases susceptibility to nocardiosis through three interrelated pathogenic mechanisms [20]: Firstly, anti-GM-CSF autoantibody impair the maturation, phagocytic capacity, and microbicidal activity of alveolar macrophages and neutrophils Secondly, pathological accumulation of pulmonary surfactant in the alveolar lumen disrupts mucociliary clearance and impairs efferocytosis of apoptotic and necrotic cellular debris, fostering a niche that promotes microbial persistence and colonization. Thirdly, diagnostic misclassification of PAP as interstitial pneumonia frequently results in inappropriate systemic glucocorticoid administration, which exacerbates infection vulnerability. Early diagnosis of PAP in patients presenting with diffuse alveolar filling disorders is essential to prevent unnecessary glucocorticoid exposure and reduce infection risk. Adjunctive GM-CSF therapy can restore alveolar macrophage function and reduce infection susceptibility by enhancing surfactant catabolism and pathogen clearance. Mabo et al. [4] reported Nocardia as the most frequent opportunistic pathogen in a large PAP cohort, and our prior epidemiological analysis confirmed PAP as an independent risk factor for Nocardia infection among immunocompetent individuals [21]. Therefore, nocardiosis should be strongly considered in PAP patients who develop new or worsening pulmonary infiltrates. Microbiological evaluation is critical to guide timely, pathogen-specific antimicrobial therapy and improve survival outcomes. Notably, elevated anti-GM-CSF autoantibody is associated with a broad-spectrum impairment of antimicrobial immunity, conferring increased susceptibility to both bacterial and fungal infections, including central nervous system (CNS) infections (predominantly due to Cryptococcus neoformans and Nocardia spp.) and systemic infections (with disseminated nocardiosis representing the most frequent clinical manifestation) [18, 21–22]. Accordingly, anti-GM-CSF autoantibody testing should be considered in all patients diagnosed with CNS nocardiosis or disseminated nocardiosis, particularly when routine immunologic evaluation is unrevealing. In case 2, anti-GM-CSF autoantibody testing was positive; however, antibody titer data were unavailable. Other three patients were admitted prior to 2015, when GM-CSF autoantibody testing was not available. Although current evidence derives from small observational studies, GM-CSF administration has demonstrated efficacy in restoring phagocyte function and improving infection control in anti-GM-CSF antibody positive patients [23]. We therefore propose that adjunctive GM-CSF therapy may represent a rational, mechanism-based strategy for patients with nocardiosis and confirmed anti-GM-CSF autoantibody positivity, which needs further validation in prospective, controlled trials. Among the four PAP cases in this study, only one underwent anti-GM-CSF autoantibody testing, which reported a positive result and inhaled GM-CSF was initiated as adjunctive therapy. Despite coexisting Nocardia and NTM infections, the patient achieved clinical improvement under combined antimicrobial and GM-CSF treatment. Serial chest imaging at 3 months showed near-complete resolution of infectious infiltrates and stabilization of PAP-associated ground-glass opacities. This favorable response aligns with GM-CSF’ s dual therapeutic effects: restoring alveolar macrophage surfactant catabolism and improving intracellular pathogen clearance. The patient subsequently underwent successful whole-lung lavage and maintained inhaled GM-CSF therapy, with progressive clinical and radiologic improvement sustained over 3 years of follow-up. Pulmonary nocardiosis commonly manifests with systemic and respiratory symptoms, including fever, productive cough, and pleuritic chest pain. HRCT typically demonstrates heterogeneous parenchymal opacities such as ground-glass attenuation, patchy consolidation, nodules, cavitation, and pleural effusion [4, 11]. The clinical and radiological features observed in the four PAP patients in our study aligned closely with these characteristics. Notably, except for Case 3 which demonstrated fulminant progression, the other three patients underwent repeated outpatient evaluations at external institutions following symptom onset but remained undiagnosed for weeks. The interval from symptom onset to confirmed nocardiosis 4–10 weeks, underscoring a substantial gap between clinical suspicion and microbiological confirmation. This diagnostic latency is attributable to the prolonged culture duration of Nocardia species which frequently require ≥ 14 days of incubation for reliable isolation [10]. Microscopic identification of weakly acid-fast or modified acid-fast filamentous bacilli in smear specimens could provide an early, highly specific clue for Nocardia infection. Metagenomic next-generation sequencing (mNGS) of respiratory has emerged as a valuable adjunctive tool, enabling rapid, unbiased pathogen detection, particularly in immunocompromised hosts with atypical presentations or prior antimicrobial exposure. If conditions permit, mNGS may be employed to assist in diagnosis. Sulfamethoxazole-trimethoprim (SMZ-TMP) remains the first-line antimicrobial agent for nocardiosis. However, recent multicenter surveillance studies report an increasing prevalence of SMZ-TMP resistance [10]. Alternative agents include linezolid, imipenem, meropenem, amikacin, minocycline, doxycycline, ceftriaxone, cefotaxime, moxifloxacin and levofloxacin. Given the heterogeneity of Nocardia species and their variable susceptibility profiles, Clinical and Laboratory Standards Institute (CLSI) guidelines strongly recommend performing in vitro antimicrobial susceptibility testing (AST) on all clinical Nocardia isolates to inform precision antimicrobial selection [10]. Combination therapy is indicated for patients with severe pulmonary disease, CNS involvement, or disseminated infection [10]. All four cases in this study underwent AST, and antimicrobial therapies were selected according to the results. Case 4 was confirmed SMZ-TMP-resistant, whereas Cases 1–3 were SMZ-TMP-sensitive. Notably, Case 1 received moxifloxacin due to a documented IgE-mediated sulfonamide hypersensitivity reaction. Treatment duration must be individualized according to host immune status, site of infection, microbiological burden, and longitudinal assessment of clinical, laboratory, and radiological response. Current consensus recommendations advise a minimum 3-month course for immunocompetent patients. For immunocompromised hosts, treatment should be extended to 6–12 months, with continuation beyond 12 months considered in cases of persistent radiographic abnormalities or recurrent infection [8]. Although prophylactic oral SMZ-TMP has been proposed for high-risk PAP patients to prevent opportunistic infections [24], this approach has not been recognized by international guidelines due to insufficient evidence. Given that active pulmonary infection constitutes an absolute contraindication to WLL [25], timely pathogen identification and rapid initiation of accurate antimicrobial therapy are critical to enable safe and effective WLL and optimize long-term outcomes in PAP patients with nocardiosis. In conclusion, in patients with PAP, the emergence of fever and new pulmonary opacities warrants strong clinical suspicion for Nocardia infection. Early initiation of pathogen-directed antimicrobial therapy is critical for infection control, which enables safe performance of whole-lung lavage, stabilizes oxygenation, prevents respiratory deterioration, and ultimately improves outcomes. Supplementary Information Supplementary Material 1. Supplementary Material 1.